New drug candidate for Alzheimer’s treatment
Alzheimer’s disease is mainly characterized by a decline of memory, stop the current therapeutic possibilities, but only slow it. Researchers from the Salk Institute (USA) have tested a promising active substance candidates in mice that could fix the memory loss.
In earlier studies had shown already indications that the active ingredient “CMS121” the aging process of the brain slows down cells, according to the research team, Pamela Maher from the Salk Institute. In the study on mice, the researchers were able to prove that the memory loss is due to the active ingredient CMS121 fix. In addition, they have shown to lead to what metabolic effects the effect. Were published the results of the study in the journal “Redox Biology”.
Substance from fruits and vegetables is the starting point
In the past few years, Pamela Maher investigated the effect of the chemical Fisetin, found in fruits and vegetables. This improves memory and can even prevent Alzheimer’s-like disease in mice, according to the researcher. In the case of the synthesis of different variants of Fisetin, the researchers found out at the Salk Institute, furthermore, that one of them, CMS121 called, improves the memory of the animals and the Degeneration of the brain slows down cells.
Treatment of mice tested
In the current study, the researchers tested the effect of CMS121 in mice with the Equivalent of human Alzheimer’s disease. The mice of the experimental group received, from the age of nine months, and only after you showed the first learning and memory problems, daily doses of CMS121. “The timing of the treatment in the laboratory is similar to the treatment of a patient who because of cognitive problems to the doctor,” explain the researchers.
Better results in memory and behavior tests
After a further three months in both treated and untreated Alzheimer’s mice were a series of memory and behavior tests. And in both types of Tests, animals that had received the drug performed, equally well as the healthy mice of a control group, while untreated mice with the disease sections of the poor, reports the researchers.
Changes in lipid levels in the brain
The scientists examined the molecular effects of CMS121 in the brains of the three groups of Mice. They found that the Lipid levels (fatty molecules) in the diseased untreated mice compared to healthy mice, and with CMS121 treated mice showed a number of differences.
These differences were evident mainly in the so-called lipid peroxidation – the removal of lipids, in the case of the free radical molecules that can cause cell damage, explain the researchers. Untreated mice with Alzheimer’s-like disease showed higher values of lipid peroxidation than healthy mice or those treated with CMS121, so the research team.
Changes in normalized actually
“This confirmed that the lipid peroxidation is altered in Alzheimer’s, but also that this drug these changes actually normalisiert”, Gamze Ates, also the first author of the new study emphasizes.
FASN, a target for drugs
Furthermore, CMS121, I have reduced the values of a lipid-producing molecule called fatty acid synthetase (FASN), which, in turn, the values of lipid peroxidation can be reduced; the researchers describe. In addition, the investigation of brain samples from deceased Alzheimer’s disease have shown patients that these higher amounts of FASN were Protein similar to that of cognitively healthy control subjects aged. This indicates that FASN could be a point of attack for drugs for the treatment of Alzheimer’s disease. “On the basis of the success of this study, we begin now with the implementation of clinical trials,” says Pamela Maher. (fp)